Press Releases April 10, 2026 08:00 AM

Enovis to Host First Quarter 2026 Results Conference Call on May 7th

Enovis announces Q1 2026 earnings call scheduled for May 7th

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ENOV

Enovis Corporation, a medical technology company listed on NYSE as ENOV, announced it will hold a conference call and webcast on May 7, 2026 to discuss its Q1 2026 financial results. The company will release its earnings press release earlier that day and provide investor materials on its website.

Enovis to Host First Quarter 2026 Results Conference Call on May 7th
ENOV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enovis will present Q1 2026 financial results on May 7, 2026, via a conference call and webcast.
  • Earnings press release to be issued earlier on the same day before the call.
  • The company focuses on medical technology innovations, particularly in orthopedics and clinically differentiated solutions.
  • The announcement impacts investors in the healthcare and medical technology sectors.

Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.

Conference Call/Webcast Information

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International callers) and use Conference ID: 3314793. A link to a replay of the call will also be available on the Enovis website later that day.

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.

Availability of Information on the Enovis Website

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.

Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com


Risks

  • Uncertainty regarding the actual Q1 2026 financial performance and whether results meet market expectations.
  • Potential for market volatility following the earnings release due to financial and operational disclosures.
  • Dependence on continued innovation and product success in the competitive medical technology and orthopedic markets.

More from Press Releases

Nuwellis Announces Closing of $6.0 Million Registered Public Offering Jun 8, 2026 Grupo Aeroportuario del Pacifico Publishes its 2025 Sustainability Report Jun 8, 2026 Cipher Digital Inc. Announces Pricing of $810.0 Million of Senior Secured Notes Jun 8, 2026 Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering Jun 8, 2026 Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation Jun 8, 2026